The study demonstrated preliminary safety and bioactivity of CART EGFR IL13Rα2 cells in recurrent glioblastoma, but evidence of efficacy remains inconclusive and requires confirmation in larger cohorts with longer follow-up periods [44]. The gene discussed is EGFR; the disease is glioblastoma.